Estats Units - anglès - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - simvastatin 5 mg - simvastatin tablets are indicated: • to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. • as an adjunct to diet to reduce low-density lipoprotein cholesterol (ldl-c):   o  in adults with primary hyperlipidemia.   o  in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (hefh). • as an adjunct to other ldl-c-lowering therapies to reduce ldl-c in adults with homozygous familial hypercholesterolemia (hofh). • as an adjunct to diet for the treatment of adults with:   o  primary dysbetalipoproteinemia.   o  hypertriglyceridemia. simvastatin  tablets are contraindicated in the following

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

genthon b.v. - simvastatin - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; simvastatin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

genthon b.v. - simvastatin - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; simvastatin

Estats Units - anglès - NLM (National Library of Medicine)

american health packaging - simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - simvastatin 10 mg - simvastatin tablets usp are indicated: - to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. - as an adjunct to diet to reduce low-density lipoprotein cholesterol (ldl-c): in adults with primary hyperlipidemia. in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (hefh). - in adults with primary hyperlipidemia. - in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (hefh). - as an adjunct to other ldl-c-lowering therapies to reduce ldl-c in adults with homozygous familial hypercholesterolemia (hofh). - as an adjunct to diet for the treatment of adults with: primary dysbeta

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - simvastatin - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; simvastatin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - simvastatin - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; simvastatin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - simvastatin - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; simvastatin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - simvastatin - film-coated tablet - 80 milligram(s) - hmg coa reductase inhibitors; simvastatin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - simvastatin - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; simvastatin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - simvastatin - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; simvastatin